Categories: News

Gilad&Gilad Is Moving South – To Texas

GEORGETOWN, Texas, March 22, 2021 /PRNewswire-PRWeb/ — Gilad&Gilad, a health science company with core competency in neuroscience, announced today that it is relocating its offices to Georgetown (Austin area), Texas. The move is an important step for the Company’s further investment in the development and marketing of its G-Agmatine®-based products. “We are relocating to Austin because of new business connections and proximity to good medical centers. The move will facilitate marketing of our signature products, AgmaSet® and AgmaVet®, which are superior for supporting proper nerve functions in humans and animals, respectively”, said Dr. Gad M. Gilad, CEO of Gilad&Gilad. “The move will also enable clinical studies aimed at substantiating the effectiveness of novel G-Agmatine®-based products in supporting additional bodily functions.

These options were not readily available in the Las Vegas area. And as a bonus, the climate is better in Austin“. Added Gilad.

Gilad&Gilad continues to maintain its contract manufacturing in South California. “We can assure our customers that the highest quality they expect of our products will be absolutely maintained.” indicated Gilad.

///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

About Gilad&Gilad LLC
Gilad&Gilad is a health science company with core competency in Neuroscience. The company has developed the exclusive Agmaceuticals(TM) line of products based on the breakthrough discovery of the neuroprotective properties agmatine. AgmaSet® (a dietary supplement) and AgmaVet® (for animals) are the first-of-their-kind nutraceuticals containing G-Agmatine® (the best brand of agmatine), with superior effectiveness for healthy nerve functions. The Company builds its reputation by continuous investment in scientific research and clinical studies. – For further information, visit https://ForNerveHealth.com.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Media Contact

GAD M. GILAD, PhD, Gilad&Gilad LLC, +1 3235990774, gmgilad@gmail.com

 

SOURCE Gilad&Gilad

Staff

Recent Posts

Neural Therapeutics Undertakes Multiple Initiatives to Defer and Eliminate a Significant Portion of Financial Obligations

Toronto, Ontario--(Newsfile Corp. - November 25, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"),…

44 minutes ago

Psyched Wellness Announces Appointment of New Director and Resignation of a Director

Toronto, Ontario--(Newsfile Corp. - November 25, 2024) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF)…

44 minutes ago

Delivra Health Brands and its Leading Brands Dream Water (R) and LivRelief(TM) Report Financial Results for First Quarter of Fiscal 2025

Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Delivra Health Brands Inc. (TSXV: DHB)…

44 minutes ago

BioGene Therapeutics Welcomes Dr. Deepak Sampath, PhD. to Its Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB:…

2 hours ago

Edison Issues Report on Care REIT (CRT)

London, United Kingdom--(Newsfile Corp. - November 25, 2024) - Edison issues report on Care REIT…

3 hours ago

Hisense Launches End-of-Year Sale in UAE with Up to 55% Discounts

DUBAI, UAE, Nov. 25, 2024 /PRNewswire/ -- Hisense, a global leader in consumer electronics and…

3 hours ago